Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals, Inc. - Common Stock (NQ:ANEB)

1.200 +0.010 (+0.84%)
Streaming Delayed Price Updated: 9:50 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Anebulo Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
News headline image
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces New CEO
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
News headline image
Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.